Multinational cooperation in trials and guidelines dealing with febrile neutropenia

Clicks: 407
ID: 119234
2000
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #7 of 23 articles by views in international journal of antimicrobial agents

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Multinational cooperation has lead to many of the advances in the therapy of cancer patients with febrile neutropenia over the last two decades and will likely continue to do so. Some of the groups and societies that have contributed to this success include the European Organization for Research and …
Reference Key
r2000internationalmultinational Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Feld R;;
Journal international journal of antimicrobial agents
Year 2000
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/11053807
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE review clinical trials as topic humans pubmed abstract nih national institutes of health national library of medicine immunocompromised host neoplasms / complications* neutropenia / complications* practice guidelines as topic anti-bacterial agents / therapeutic use* fever / complications* r feld infections / drug therapy* pmid:11053807 doi:10.1016/s0924-8579(00)00240-5 international cooperation*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.